Cidara Therapeutics, Inc. (CDTX) — Current Report

Key Insights

• Cidara Therapeutics, Inc. has been acquired by Merck Sharp & Dohme LLC through a tender offer and subsequent merger, resulting in Cidara becoming a wholly-owned subsidiary of Merck.
• The acquisition was completed on January 7, 2026, after Merck's subsidiary acquired approximately 88.3% of Cidara's outstanding shares through the tender offer.
• As part of the acquisition, Cidara has terminated its various equity incentive plans, including the 2015 Equity Incentive Plan, the 2020 Inducement Incentive Plan, the 2024 Equity Incentive Plan, and the 2015 Employee Stock Purchase Plan.